title: Antiresorptive drug-related osteonecrosis of the jaw.
abstract: Nitrogen-containing and non-nitrogen-containing bisphosphonates have been implicated in the development of osteonecrosis of the jaw (ONJ), a condition termed bisphosphonate-related OHJ. Other antiresorptive drugs have been implicated in the development of OHJ, hence the new term antiresorptive drug-related ONJ. The underlying pathogenesis remains unclear, and no definite diagnosis or cure has been established for this debilitating condition. This article reviews some of the most common antiresorptive drugs with their associated risks of ONJ and the current understanding of the pathogenesis ONJ, and summarizes current clinical guidelines.
authors.affiliation: Division of Oral and Maxillofacial Surgery, Herman Ostrow School of Dentistry of USC, 925 West 34th Street, Los Angeles, CA 90089-0641, USA; Division of Oral and Maxillofacial Surgery, Harbor UCLA, 1000 West Carson Street, Torrance, CA 90509, USA. Electronic address: uyanne@usc.edu.
authors.forename: Jettie
authors.initials: J
authors.lastname: Uyanne
authors.affiliation: Division of Oral and Maxillofacial Surgery, Harbor UCLA, 1000 West Carson Street, Mailbox #19, Torrance, CA 90509, USA; Charles R. Drew University, Los Angeles, CA, USA.
authors.forename: Colonya C
authors.initials: CC
authors.lastname: Calhoun
authors.affiliation: Division of Oral and Maxillofacial Surgery, Herman Ostrow School of Dentistry of USC, 925 West 34th Street, Los Angeles, CA 90089-0641, USA; Department of Oral and Maxillofacial Surgery and Pharmacology, University of Pennsylvania School of Dental Medicine, Penn Medicine Hospital of the University of Pennsylvania, 240 South 40th Street, Philadelphia, PA 19104-6030, USA.
authors.forename: Anh D
authors.initials: AD
authors.lastname: Le
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000175:diagnosis / Q000209:etiology*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D000069448:Denosumab; D004164:Diphosphonates / Q000009:adverse effects; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000175:diagnosis; D010020:Osteonecrosis / Q000139:chemically induced* / Q000175:diagnosis; D053245:RANK Ligand / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D053245:RANK Ligand; D000069448:Denosumab
keywords: Bisphosphonate; Denosumab; Osteonecrosis of the jaw; Zoledronate